title: Rethinking the reasons to treat atrial fibrillation? The role of dronedarone in reducing cardiovascular hospitalizations.
authors.affiliation: Department of Cardiology, Harvard Vanguard Medical Associates, Boston, MA 02215, USA. rfalk@partners.org
authors.forename: Rodney H
authors.initials: RH
authors.lastname: Falk
authors.forename: A John
authors.initials: AJ
authors.lastname: Camm
mesh_terms: D000638:Amiodarone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D000077764:Dronedarone; D006760:Hospitalization; D006801:Humans; D012307:Risk Factors
chemical_list: D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone